摘要
原发免疫性血小板减少症(ITP)是一种获得性自身免疫性出血性疾病,成人ITP的发病率约为(2~10)/10万。妊娠合并ITP是妊娠期血小板减少的常见病因,约占3%~5%,主要表现为妊娠早期的血小板减少。妊娠合并ITP的治疗方法以减少母体及新生儿不良出血事件为基本原则,首选药物治疗。治疗药物包括糖皮质激素、重组人血小板生成素等。妊娠合并ITP的管理须贯穿妊娠全程,其中孕前咨询、孕期监测与治疗、分娩时机和分娩方式的选择、新生儿血小板检测均需重点关注。
Primary immune thrombocytopenia(ITP)is an acquired autoimmune hemorrhagic disease.The incidence of ITP in adults is about(2-10)/100 000.ITP during pregnancy is a common cause of pregnancy with thrombocytopenia,accounting for about 3%-5%.It is mainly manifested as thrombocytopenia in early pregnancy.The basic principle of the treatment for ITP during pregnancy is preventing maternal and neonatal adverse bleeding events.The first-choice treatment is drug therapy,including glucocorticoids,recombinant human thrombopoietin,etc.The management of ITP during pregnancy must run throughout pregnancy,focusing on pre-conception counseling,monitoring and treatment during pregnancy,selection of delivery timing and mode,and neonatal platelet testing.
作者
张姝文
乔宠
ZHANG Shu-wen;QIAO Chong(Department of Obstetrics and Gynecology,Shengjing Hospital of China Medical University,Shenyang 110000,China)
出处
《中国实用妇科与产科杂志》
CAS
CSCD
北大核心
2022年第12期1170-1173,共4页
Chinese Journal of Practical Gynecology and Obstetrics
基金
国家自然科学基金面上项目(81370735,81771610)
国家重点研发计划(2016YFC1000404)
辽宁省民生科技计划联合计划项目(2021JH2/10300123)
沈阳市科技计划项目(20-205-4-004)
盛京自由研究者基金(201706)
辽宁省特聘教授(2017)
百千万人才工程领军人才(XLYC2005008)。
